NCT00265239

Pilot Study of Edaravone to Treat Acute Myocardial Infarction

Effects of Edaravone in Patients With Acute Myocardial Infarction

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 104 (actual)
• Sponsor: Kumamoto University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.

Detailed description

Initial AMI patients were randomly assigned to receive 30 mg of edaravone or a placebo intravenously just before reperfusion. We compared infarct size, using serial determination of serum biomarkers and Q wave formations, and the incidence of reperfusion arrhythmia between the groups. Cardiovascular event-free curves were estimated by Kaplan-Meier method. In addition, we determined serum thioredoxin levels, an oxidative stress marker, to assess the antioxidant effect of edaravone.

Conditions

• Myocardial Infarction
• Reperfusion Injury

Interventions

Type	Name	Description
DRUG	edaravone	intravenous administration of 30mg Edaravone just before reperfusion therapy

Timeline

• Start date: 2001-04-01
• Completion: 2007-06-01
• First posted: 2005-12-14
• Last updated: 2014-09-15
• Results posted: 2014-09-15

Locations

1 site across 1 country: Japan